Feasibility and validity of the Patient Neurotoxicity Questionnaire during taxane chemotherapy in a phase III randomized trial in patients with breast cancer: N-SAS BC 02-Reference-Cited by-同舟云学术

Feasibility and validity of the Patient Neurotoxicity Questionnaire during taxane chemotherapy in a phase III randomized trial in patients with breast cancer: N-SAS BC 02

Published:2009-03-28 Issue:12 Volume:17 Page:1483-1491
ISSN:0941-4355
Container-title:Supportive Care in Cancer
language:en
Short-container-title:Support Care Cancer

Author:

Shimozuma Kojiro,Ohashi Yasuo,Takeuchi Ayano,Aranishi Toshihiko,Morita Satoshi,Kuroi Katsumasa,Ohsumi Shozo,Makino Haruhiko,Mukai Hirohumi,Katsumata Noriyuki,Sunada Yoshihide,Watanabe Toru,Hausheer Frederick H.

Publisher

Springer Science and Business Media LLC

Subject

Oncology

Link

http://link.springer.com/content/pdf/10.1007/s00520-009-0613-7.pdf

Reference29 articles.

1. Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, Filiberti A, Flechtner H, Fleishman SB, de Haes JCJM, Kaasa S, Klee M, Osoba D, Razavi D, Rofe PB, Schraub S, Sneeuw K, Sullivan M, Takeda F, European Organization for Research and Treatment of Cancer Study Group on Quality of Life (1993) The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85:365–376. doi: 10.1093/jnci/85.5.365

2. Ajani JA, Welch SR, Raber MN, Fields WS, Krakoff IH (1990) Comprehensive criteria for assessing therapy-induced toxicity. Cancer Invest 8:147–159. doi: 10.3109/07357909009017560

3. Basch E, Lasonos A, McDonough T, Barz A, Culkin A, Kris MG, Scher HI, Schrag D (2006) Patient versus clinician symptom reporting using the National Cancer Institute Common Terminology Criteria for Adverse Events: results of a questionnaire-based study. Lancet Oncol 7:903–909. doi: 10.1016/S1470-2045(06)70910-X

4. Boehmke MM, Dickerson SS (2005) Symptom, symptom experiences, and symptom distress encountered by women with breast cancer undergoing current treatment modalities. Cancer Nurs 28:382–389. doi: 10.1097/00002820-200509000-00008

5. Bonomi AE, Cella DF, Hahn EA, Bjordai K, Sperner-Unterweger B, Gangeri L, Bergman B, Willems-Groot J, Hanquet P, Zittoun R (1996) Multilingual translation of the Functional Assessment of Cancer Therapy (FACT) quality of life measurement system. Qual Life Res 5:309–320. doi: 10.1007/BF00433915

Cited by 155 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A randomized, open-label phase II study on the preventive effect of goshajinkigan against peripheral neuropathy induced by paclitaxel-containing chemotherapy: The OLCSG2101 study protocol;Respiratory Investigation;2024-09

2. Psychometric properties and longitudinal measurement invariance of the Treatment-induced Neuropathy Assessment Scale in the Chinese cancer chemotherapy population;2024-08-17

3. Blood biomarkers for neuroaxonal injury and astrocytic activation in chemotherapy-induced peripheral neuropathy;Acta Oncologica;2024-08-05

4. Quality-of-life survey of pancreatic cancer patients: a comparison between general public and physicians;Frontiers in Health Services;2024-07-12

5. Efficacy of cryotherapy in the prevention of chemotherapy-induced peripheral neuropathy: A systematic review and meta-analysis;Supportive Care in Cancer;2024-07